medigraphic.com

2015, Número 5

<< Anterior Siguiente >>

Rev Clin Esc Med 2015; 5 (5)


Ganglio centinela en el melanoma cutáneo

Piccolo JL, Brenes LE

Idioma: Español
Referencias bibliográficas: 54
Paginas: 52-61
Archivo PDF: 956.85 Kb.


RESUMEN

La biopsia del ganglio centinela se considera una herramienta diagnóstica con gran poder pronóstico y de estadiaje ya que permite detectar enfermedad nodal clínicamente negativa debajo del umbral de cualquier otra técnica no patológica (incluyendo modalidades de imágenes). Es el único examen diagnóstico con tanto alta sensibilidad como especificidad. Bajo este concepto se han desarrollado múltiples estudios comparando su utilidad como predictor de metástasis y mortalidad; tomando esto en consideración, varias guías han surgido.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bailey E Sober A Tsao H Mihm M Johnson T. Cutaneous Melanoma: en Fitzpatrick´s Dermatology in General Medicine. Editorial Mc Graw Hill Companies, Inc. Estados Unidos de América. 8va edición, 2012;Pp: 1425- 1427.

  2. Bichakjian CK. Halpern AC Johnson TM et al. Guidelines of care for the management of primary cutaneous melanoma. J Am AcadDermatol 2011;65:1032-47.

  3. Gershenwald JE Ross MI. Sentinel- Lymph-Node Biopsy for Cutaneous Melanoma. N Eng J Med 2011;364:1738- 45.

  4. Gershewald JE Coit DG Sondak VK Thompson JF. The Challenge of Defining Guidelines for Sentinel Lymph Node Biopsy in Patients with Thin Primary Cutaneous Melanoma. Ann SurgOncol 2012:1-3.

  5. Phan GQ Messina JL Sondal VK Zager JS. Sentinel Lymph Node Biopsy for Melanoma: Indications and Rationale. Cancer Control 2009;16(3):234-239.

  6. Bailer E Sober AJ Tsao H Mihm MC Johnson TM. Chapter 124: Cutaneous Melanoma.En Fitzpatrick ´sDermatology in General Medicine. 8va Edición. http://accessmedicine.mhmedical.com.e zproxy.sibdi.ucr.ac.cr:2048/content.asp x?bookid=392§ionid=41138842&j umpsectionID= 41153922&Resultclick=2Accesad o 25 mayo, 2014.

  7. Ludgate MW Johnson TM Wang TS. Chapter 100: Skin Cancer. En Hazzard` s Geriatric Medicine and Gerontology, 6ta Edición. http://accessmedicine.mhmedical.com.e zproxy.sibdi.ucr.ac.cr:2048/content.asp x?bookid=371§ionid=41587719&j umpsectionID= 41597346&Resultclick=2Accesad o 20 mayo, 2014.

  8. Heistein Jonathan B Melanoma. Medscape. Abril, 2014. http://emedicine.medscape.com/article/ 1295718-overview.Accesado 14 mayo, 2014.

  9. Piccolo L Chan A. Melanoma AcralLentiginoso: una entidad a tener en cuenta en la práctica diaria. Rev Cl EMed UCR. Vol 3, No VI, 2013. Pp:15- 19.

  10. Tan Wiston W. Malignant Melanoma. Medscape. Abril, 2014. http://emedicine.medscape.com/article/ 280245-overview . Accesado 14 mayo, 2014.

  11. Section 12. Melanoma Precursors and Primary Cutaneous Melanoma. In: Wolff K, Johnson R, Saavedra AP. eds. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 7ma edición. http://accessmedicine.mhmedical.com.e zproxy.sibdi.ucr.ac.cr:2048/content.asp x?bookid=682&Sectionid=45130143. Accesado 14 Mayo, 2014.

  12. Stoffels I Boy C Pöppel, T et al. Association Between Sentinel Lymph Node Excision With or Without Preoperative SPECT/CT and Metastatic Node Detection and Disease-Free Survival in Melanoma. JAMA. 2012;308(10):1007- 1014.

  13. Durham AB Wong SL. Sentinel Lymph Node Biopsy in Melanoma. Controversies and Current Guidelines. Future Oncol. 2014, 10(3):429-42.

  14. Lee JH Essner,R Torisu-Itakura H Wanek L Wang H Morton DL. Lymph Nodes After Tumor-Positive Sentinel Lymph Node Dissection for Melanoma. J ClinOncol 2001;22:3677-3684.

  15. Berk, DR Johnson DL Uzieblo A Kierman, M Swetter SM. Sentinel Lymph Node Biopsy for Cutaneous Melanoma. TheSanfordExperience, 1997- 2004.ArchDermatol. 2005;141:1016- 1022.

  16. Heiken, TJ. The Role of Sentinel Node Biopsy in Skin Cancer. Medscape. Marzo, 2014. http://emedicine.medscape.com/article/ 1126050-overview.Accesado 20 Mayo, 2014.

  17. Elias N Tanabe KK .Sober AJ et al. Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary? ArchSurg. 2004;139:400-405.

  18. Lee JH Essner R Torisu-Itakura H Wanek, L Wang H Morton DL. Factors Predictive of Tumor-Positive Nonsentinel Lymph Nodes After Tumor-Positive Sentinel Lymph Node Dissection for Melanoma. J ClinOncol 2004;22:3677- 3684.

  19. Kim KB Davies MA Rapini RP Hwu, P Bedikian AY. Chapter 39: Malignant Melanoma. En The MD Anderson Manual of Medical Oncology, 2da edición. http://accessmedicine.mhmedical.com.e zproxy.sibdi.ucr.ac.cr:2048/content.asp x?bookid=379§ionid=39902069&j umpsectionID= 39908241&Resultclick=2Accesad o: 16 mayo, 2014.

  20. Cole P Heller L Bullocks J Hollier LH. Stal, S. Chapter 16: The Skin and Subcutaneous Tissue. En Schwartz´s Principles of Surgery, 9na edición. http://accessmedicine.mhmedical.com.e zproxy.sibdi.ucr.ac.cr:2048/content.asp x?bookid=352§ionid=40039758&j umpsectionID= 40043331&Resultclick=2Accesad o 25 mayo, 2014.

  21. Polk HC Qadan. M. Chapter 30: Malignant Melanoma and Squamous Cell Carcinoma of the Skin. En: Fischer´s Mastery of Surgery. 6ta edición. Editorial Wolters Kluwer Health. Pp: 394- 400.

  22. Sabel MS. Chapter 44: Oncology. En: CURRENT Diagnosis & Treatment: Surgery. 13va edición. http://accesssurgery.mhmedical.com.ez proxy.sibdi.ucr.ac.cr:2048/content.aspx ?bookid= 343§ionid=39702832&jumpse ctionID=39716887&Resultclick=2. Accesado: 26 mayo, 2014.

  23. Goydos JS. Who Should Be Offered a Sentinel Node Biopsy for Melanoma Less Than 1 mm in Thickness?J ClinOncol 2013;31(35):4385-4386.

  24. Morton DL Thompson JF Cochran AJ et al. Final Trial Report of Sentinel- Node Biopsy versus Nodal Observation in Melanoma.N Engl J Med 2014;370:599-609.

  25. Prieto VG Curry JL. Sentinel Lymph Node Biopsy in Melanoma Pathology. Medscape. Octubre, 2013. http://emedicine.medscape.com/article/ 1977004-overview. Accesado 21 Mayo, 2014.

  26. Stone M. Evaluation and treatment of regional lymph nodes in melanoma. UpToDate. Febrero 2014. http://www.uptodate.com.ezproxy.sibdi. ucr.ac.cr:2048/contents/evaluation-andtreatment- of-regional-lymph-nodes-inmelanoma? source=search_result&search=evalu ation+and+tratment+of+regional+lymp h+nodes+in+melanoma&selectedTitle= 1%7E150.Accesado 22 Mayo, 2014.

  27. Martí E Díaz AJ Martín M et al. El ganglio centinela en el melanoma: nuestra experiencia. CirPlasIberolatinoam. 2006;32(2):117-126.

  28. NCCN Clinical Practice Guidelines in Oncology. Melanoma. Versión 4.2014 http://www.nccn.org/professionals/phys ician_gls/PDF/melanoma.pdf. Accesado 15 Mayo, 2014.

  29. Urba WJ Washington CV Nadiminti H. Chapter 87: Cancer of the Skin. En Harrison´sPrinciples of Internal Medicine, 18va edición. http://accessmedicine.mhmedical.com.e zproxy.sibdi.ucr.ac.cr:2048/content.asp x?bookid=331§ionid=40726823Ac cesado 25 mayo, 2014.

  30. Sondak VK. King DW Zager JS et al. Combined Analysis of Phase III Trials Evaluating 99mTcTilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node- Negative Cutaneous Melanoma. Ann SurgOncol 2013;20:680-688.

  31. Keidan RD Fong P Kestenberg WL. Sentinel Lymph Node Biopsy in Patients With Melanoma. Medscape. Abril, 2014. http://emedicine.medscape.com/article/ 854424-overview#showall. Accesado 20 Mayo, 2014.

  32. Schmalbach CE Nussenbaum B Rees RS Schwartz J Johnson TM Bradford CR. Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma. ArchOtolaryngol Head NeckSurg. 2003;129:61-65.

  33. Valsecchi ME Silbermins D de Rosa N Wong SL Lyman GH. Lymphatic Map ping and Sentinel Lymph Node Biopsy in Patients With Melanoma: A Meta- Analysis.J ClinOncol. 2011;29:1479- 1487.

  34. Morton DL Wen DR Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 1992;127(4):392– 399.

  35. Morton DL. Overview and Update of the Phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in Melanoma.ClinExp Metastasis 2012;29(7):699-706.

  36. Morton DL Thompson JF Cochran AJ et al. Sentinel-Node Biopsy or Nodal Observation in Melanoma. N Eng J Med 2006;355:1307-17.

  37. U.S. National Institutes of Health. Clinical Trials. Multicenter Selective Lymphadenectomy Trial II (MSLT-II). Abril, 2014. http://clinicaltrials.gov/show/NCT0029 7895 . Accesado 17 Mayo, 2014.

  38. Nelson R. Lack of Clear Evidence for Sentinel Node Bioppsy in Melanoma? Medscape. Enero, 2013. http://www.medscape.com/viewarticle/7 77518 .Accesado 21 Mayo, 2014.

  39. Scoggins CR Bowen AL Martin RC et al. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma. ArchSurg 2010;145(7):622-627.

  40. McMasters KM Chao C Wong SL et al. IntervalSentinelLymphNodes in Melanoma. ArchSurg. 2002;137:543-549.

  41. Cadili, A.; Dabbs, K. Predictors of sentinel lymph node metastasis in melanoma. J can chir. 2010;53(1):32-36.

  42. Han D Zager JS Shyr, Y et al. Clinicopathological Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma. J ClinOncol 2013;31:4387-4393.

  43. Ulmer A Dietz K Hodak I et al. Quantitative Measurement of Melanoma Spread in Sentinel Lymph Nodes and Survival. PLoSMed 2014;11(2):e1001604, doi:10.1371/journal.pmed.1001604.

  44. Nagaraja V Eslick GD. Is complete lymph node dissection after a positive sentinel lymph node biosy for cutaneous melanoma always necessary? A metaanalysis. EJSO 2013;39:669-680.

  45. European Organization for Research and Treatment of Cancer. Melanoma Group. EORTC 1208: MINITUB Registration Study.Octubre, 2013. http://www.melanomagroup.eu/site/data basefor-melanoma-groupmember/ minitub.html. Accesado 18 Mayo, 2014.

  46. U.S. National Institutes of Health. Clinical Trials. Minimal SN Tumor Burden (Minitub). Setiembre, 2013. http://clinicaltrials.gov/show/NCT0194 2603.Accesado 20 Mayo, 2014.

  47. Ariyan CE Coit DG. Clinical aspects of sentinel lymph node biopsy in melanoma. SeminDiagnPathol 2008;25(2):86- 94.

  48. Carlson GW Murray DR Greenlee R et al. Management of Malignant Melanoma of the Head and Neck Using Dynamic Lymphoscintigraphy and Gamma Probe-Guided Sentinel Lymph Node Biopsy. ArchOtolaryngol Head NeckSurg. 2000;126:433-437.

  49. Fincher TR O´Brien JC McCarty TM et al. Patterns of Drainage and Recurrence Following Sentinel Lymph Node Biopsy for Cutaneous Melanoma of the Head and Neck.ArchOtolaryngol Head NeckSurg. 2004;130:844-848.

  50. Agnese DM Maupin R Tillman B Pozderac RD Magro C Walker MJ. Head and Neck Melanoma in the Sentinel Lymph Node Era. ArchOtolaryngol Head NeckSurg. 2007;133(11):1121- 1124.

  51. Esmaeli B. Sentinel Lymph Node Biopsy Is Not Relevant to Perineural Invasion for Eyelid Melanomas. ArchOphthalmol 2008;26(11):1607.

  52. Roaten JB Pearlman N Gonzalez R Gonzalez R McCarter MD. Identifying Risk Factors for Complications Following Sentinel Lymph Node Biopsy for Melanoma.ArchSurg 2005;140:85-89.

  53. Wrone DA Tanabe KK Cosimi B Gadd MA Souba WW Sober AJ. LymphedemaAfterSentinelLymphNodeBiopsyfor- Cutaneous Melanoma. A report of 5 cases. ArchDermatol. 2000;136:511- 514.

  54. Dubois RW Swetter SM Atkins M et al. Developing Indications for the Use of Sentinel Lymph Node Biopsy and Adjuvant High-Dose Interferon Alfa-2b in Melanoma. ArchDermatol. 2001;137:1217-1224.




2020     |     www.medigraphic.com